12.06.2023 09:00
Oculis, a global biopharmaceutical company focussing on eye care, successfully closed a follow-on financing of $40 million. The company intends to use the net proceeds from this offering, together with its existing resources, to fund its development programs in Diabetic Macular Edema and other ophthalmic indications, and for working capital and general corporate purposes.